Return to homepagePandemic Pact

Viral and Immunological correlates of clinical severity and response to anti-viral therapy for Covid-19

Grant number: COV/GLA/20/07

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $396,146.52

  • Funder

    CSO Scotland

  • Principal Investigator

    Prof. Carl Goodyear

  • Research Location

    United Kingdom

  • Lead Research Institution

    University of Glasgow

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The clinical outcome of COVID-19 is ultimately determined by viral replication in the face of the host immunity. The latter can either control viral infection or exacerbate disease due to uncontrolled inflammatory processes that damages tissues. Hence, in order to establish the efficacy of antiviral therapies and determine whether stratification can aid clinical decisions in COVID19 patients, we need to identify correlates of disease severity and response to treatment. This proposal aims to fully determine the dynamic viral and immunological changes occurring during the different clinical stages of COVID-19. We will use a clinical trial for Favipiravir (GETAFIX, GLA3), an antiviral drug as our test case to develop our biomarkers but can roll this project out to support other trials within ASTERIX (GLA2).